---
title: "Amplify's weight-loss ETF and Gabelli's high-income ETF will liquidate"
url: "https://etf.net/news/amplify-gabelli-etfs-will-liquidate-2026-11-11"
published_at: "2026-11-11T00:44:38.936Z"
updated_at: "2026-11-11T00:44:38.936Z"
byline: "ETF.net Research"
---

# Amplify's weight-loss ETF and Gabelli's high-income ETF will liquidate

Shareholders can sell Amplify's weight-loss ETF through the Dec. 3 close, and Gabelli's high-income ETF through a last trading day, on or about Dec. 11, that officers may change without notice.

By ETF.net Research. Published Nov 10, 2026.

Amplify ETF Trust's board of trustees voted on Tuesday, Nov. 10, 2026, to terminate and liquidate the Amplify Weight Loss Drug & Treatment ETF THNR. A prospectus supplement filed the same day says Gabelli ETFs Trust's board of trustees has approved a plan to liquidate the Gabelli High Income ETF GBHI.

The two supplements are updates to the prospectus each fund already has. They are the only Tuesday filings with the U.S. Securities and Exchange Commission that set a fund to close.

The deadlines differ. Selling on NYSE Arca, where both funds are listed, gets the market price. A holder who still has shares is redeemed for cash at net asset value, the per-share value of what the fund owns.

The [Gabelli supplement](https://www.sec.gov/Archives/edgar/data/1748425/000182912626012203/gabelli_497.htm) says there can be no assurance a broker-dealer will buy the shares, or that there will be a market.

Table: Fund, Last day to sell, Cash if you still hold

THNR tracks the VettaFi Weight Loss Drug & Treatment Index. The [Amplify supplement](https://www.sec.gov/Archives/edgar/data/1633061/000121390026118064/ea0311567-01_497.htm) says that while the fund winds down, it may hold cash, and may principally hold cash. It may also hold securities that may not be consistent with its objective and strategy. A sale may carry the broker's usual charge.

The same Gabelli supplement says that, effective immediately, GBHI will begin liquidating its portfolio and will no longer pursue its objective. It says the proceeds equal net asset value after the fund has paid or provided for its charges, taxes, expenses and liabilities. A sale carries the usual charges.

Both supplements refer holders to their own tax advisers. Amplify's says a redemption generally produces a capital gain or loss. Gabelli's says a sale or a redemption generally does.

Amplify gives (855) 267-3837 for questions. Gabelli gives (800) 422-3554.

The filings that follow were made Monday, Nov. 9, except Vanguard's prospectus, which was filed Tuesday and became effective that day.

## iShares states total expenses of 0.46% for IDYN

BlackRock ETF Trust's [prospectus dated Nov. 9](https://www.sec.gov/Archives/edgar/data/1761055/000119312526453435/d25739d485bpos.htm) states total annual fund operating expenses of 0.46% for the iShares International Equity Factor Rotation Active ETF IDYN. The same prospectus dates the start of operations to Aug. 5, 2025, and is marked to take effect immediately.

The [prospectus dated July 9, 2025](https://www.sec.gov/Archives/edgar/data/1761055/000119312525157097/d902234d485bpos.htm) stated 0.45%. The management fee is 0.45% in both. Other expenses are now 0.01%. The July prospectus estimated them at 0.00%.

## Funds that had not commenced operations

Table: Fund, Total annual fund operating expenses, What the filing says

The Vanguard prospectus says VEMB is not a share class of the Vanguard Emerging Markets Bond Fund, and should not be confused with it.

The Leverage Shares funds are not described as funds that seek a daily multiple. Each seeks long-term capital appreciation and may use swaps for its exposure to the named group. That prospectus says the cost of those swaps is not included in the 0.55%, and is not in the expense example.

Source: etf.net, https://etf.net/news/amplify-gabelli-etfs-will-liquidate-2026-11-11. Please cite the page URL.